|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7259186||ABBVIE||Salts of fenofibric acid and pharmaceutical formulations thereof|| |
(1 year, 3 months from now)
Trilipix is owned by Abbvie.
Trilipix contains Choline Fenofibrate.
Trilipix has a total of 1 drug patent out of which 0 drug patents have expired.
Trilipix was authorised for market use on 15 December, 2008.
Trilipix is available in capsule, delayed release;oral dosage forms.
The generics of Trilipix are possible to be released after 07 January, 2025.
Market Authorisation Date: 15 December, 2008
Dosage: CAPSULE, DELAYED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic